---
schema_version: "secwatch.filing_event.v1"
accession: "0001603756-24-000061"
form_type: "8-K"
ticker: null
cik: "0001603756"
company_name: "Axonics, Inc."
filed_at: "2024-04-30T23:59:59+00:00"
generated_at: "2026-06-03T04:27:33.818130+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Axonics Q1 revenue $91.4M, up 29% YoY; gross margin record 75.8%

## Summary
- Net loss $19.1M vs $9.2M prior year, includes $3.8M acquisition costs for Boston Scientific merger.
- Sacral neuromodulation revenue $71.7M (+30%), Bulkamid revenue $19.7M (+27%).
- Adjusted EBITDA $3.0M vs $0.9M prior year; $6M cash compensation added back due to halted equity grants.
- Cash and investments $349M as of March 31, 2024; no guidance issued.
- Pending merger with Boston Scientific; equity grants stopped Jan 2024, shifting $6M to cash compensation.

## SEC filing metadata
- accession: 0001603756-24-000061
- form_type: 8-K
- cik: 0001603756
- company_name: Axonics, Inc.
- filed_at: 2024-04-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1603756/000160375624000061/0001603756-24-000061-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1603756/000160375624000061/axnx-20240430.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001603756-24-000061
- JSON: https://secwatch.observer/filing/0001603756-24-000061.json
- Plain text: https://secwatch.observer/filing/0001603756-24-000061.txt

## Key facts
- Earnings Releases
  Axonics, Inc. reported three months ended March 31, 2024 results: revenue $91.4 million, net income Net loss was $19.1 million.
  - Period: three months ended March 31, 2024
  - Revenue: $91.4 million
  - Net income: Net loss was $19.1 million
  - Result: reported results
  source text: of Boston Scientific as we endeavor to bring our life-changing incontinence therapies to more patients than ever before.” First Quarter 2024 Financial Results • Net revenue was $91.4 million, an increase of 29% compared to the prior year period. ◦ Sacral neuromodulation revenue was $71.7 million, an increase of 30% compared to the prior year period. ◦ Bulkamid
  evidence_url: https://www.sec.gov/Archives/edgar/data/1603756/000160375624000061/0001603756-24-000061-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.